ALX follows Gilead in axing CD47 blood cancer trials as data disappoint

The dream of using anti-CD47 drugs to boost chemotherapy in blood cancer patients is unraveling fast. Weeks after Gilead Sciences stopped its phase 3 trial for futility, ALX Oncology has called a halt to a pair of studies for a rival therapy.